Orthonika Ltd.
Total meniscus replacement
This article was originally published in Start Up
Executive Summary
Orthonika Ltd., a spin-out from Imperial College London, is developing TMR, which it describes as the first total knee meniscus replacement. The start-up's implant is based on a proprietary polymer substrate that mimics the structure and function of the healthy meniscus, and the attachment mechanisms to the bone.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.